


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:17Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406371" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406371</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcgast</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Gastroenterol</journal-id><journal-id journal-id-type="pmc-domain-id">30</journal-id><journal-id journal-id-type="pmc-domain">bmcgast</journal-id><journal-title-group><journal-title>BMC Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">1471-230X</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406371</article-id><article-id pub-id-type="pmcid-ver">PMC12406371.1</article-id><article-id pub-id-type="pmcaid">12406371</article-id><article-id pub-id-type="pmcaiid">12406371</article-id><article-id pub-id-type="pmid">40898073</article-id><article-id pub-id-type="doi">10.1186/s12876-025-04234-x</article-id><article-id pub-id-type="publisher-id">4234</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Acute versus acute-on-chronic liver failure: comparative analysis of clinical outcomes in Beijing, China</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="H">Hebing</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="N">Ningning</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Liu</surname><given-names initials="J">Jingyuan</given-names></name><address><email>dtyyicu@ccmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Li</surname><given-names initials="A">Ang</given-names></name><address><email>liang@ccmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/013xs5b60</institution-id><institution-id institution-id-type="GRID">grid.24696.3f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0369 153X</institution-id><institution>Department of Critical Care Medicine, Beijing Ditan Hospital, </institution><institution>Capital Medical University, </institution></institution-wrap> Chaoyang District, Beijing, 100015 China </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478338</issue-id><elocation-id>637</elocation-id><history><date date-type="received"><day>7</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>7</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12876_2025_Article_4234.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) pose significant threats to patient outcomes, frequently resulting in multiple organ dysfunction syndrome (MODS) and elevated mortality rates. This study investigates MODS outcomes among ALF and ACLF patients in China, identifying key factors that influence mortality and prognosis.</p></sec><sec><title>Methods</title><p id="Par2">A retrospective cohort analysis was conducted at a specialized tertiary hospital in Beijing, covering the period from June 2009 to May 2022, which included 585 patients:195 with ALF and 390 with ACLF.</p></sec><sec><title>Results</title><p id="Par3">Among these, 61% of ALF patients and 45.1% of ACLF patients developed MODS. ALF patients exhibited a higher incidence of organ failures and significantly higher median admission critical illness scores. Multivariate logistic regression analysis identified age, number of organ failures, and platelet count as independent predictors of 90-day mortality. Kaplan-Meier survival hazards analysis revealed significantly higher 90-day cumulative mortality rates for ALF patients compared to ACLF patients (33.8% vs. 25.9%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.009).</p></sec><sec><title>Conclusion</title><p id="Par4">Approximately 50% of liver failure patients progress to MODS, with ALF patients demonstrating a higher incidence of MODS and poorer 90-day prognoses.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12876-025-04234-x.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Clinical outcomes</kwd><kwd>Multiple organ dysfunction syndrome</kwd><kwd>Acute liver failure</kwd><kwd>Acute-on-chronic liver failure</kwd><kwd>Cohort study</kwd></kwd-group><funding-group><award-group><funding-source><institution>Beijing Research Ward Excellence Program</institution></funding-source><award-id>BRWEP2024W102170109</award-id><award-id>BRWEP2024W102170109</award-id><principal-award-recipient><name name-style="western"><surname>Guo</surname><given-names>Hebing</given-names></name><name name-style="western"><surname>Li</surname><given-names>Ang</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>National clinical key specialty construction project and Capital health development research project</institution></funding-source><award-id>2023-NO.492</award-id><principal-award-recipient><name name-style="western"><surname>Liu</surname><given-names>Jingyuan</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par34">Liver diseases affect more than 50% of the global population and are responsible for approximately 62.6% of deaths in the Asia Pacific region [<xref ref-type="bibr" rid="CR1">1</xref>]. Liver failure (LF) is characterized by the impaired function of multiple major organ systems, including the liver, coagulation system, central nervous system, kidneys, circulatory system, and respiratory system, accompanied by systemic inflammation. This condition may be precipitated by acute factors [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par35">Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are the two primary forms of liver failure. Typically, both conditions are associated with a poor prognosis and pose substantial challenges globally, leading to high mortality rates and imposing significant societal burdens [<xref ref-type="bibr" rid="CR3">3</xref>]. ALF occurs in patients with a normal liver, while ACLF occurs in patients with or without a previous diagnosis of chronic liver disease or cirrhosis. Both conditions can potentially result in the development of sequential multiple organ dysfunction syndrome (MODS), thereby increasing the risk of mortality and adverse functional outcomes. This progression contributes to elevated short-term (28-day) mortality rates [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par36">However, there are relatively few research related to these two types of liver failure. Furthermore, the strategies employed for managing organ failure in general critical care settings may not be entirely suitable for patients with liver failure. Early identification and effective management of liver failure and its associated complications can potentially improve patient outcome [<xref ref-type="bibr" rid="CR6">6</xref>]. This study aims to compare the occurrences of MODS and the prognoses of patients with two types of liver failure.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study population</title><p id="Par37">This was a single-center, retrospective cohort study conducted at the Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, a renowned institution for infectious diseases. The study employed a retrospective design and involved a comprehensive review of data extracted from the Hospital Information System (HIS) spanning from June 1, 2009, to May 31, 2022.</p><p id="Par38">The inclusion criteria were as follows: (1) individuals diagnosed with ALF or ACLF; (2) age&#8201;&#8805;&#8201;18 years.</p><p id="Par39">Exclusion criteria included: (1) patients with hepatocellular carcinoma or other malignancies(<italic toggle="yes">n</italic>&#8201;=&#8201;29); (2) incomplete medical records(<italic toggle="yes">n</italic>&#8201;=&#8201;19); (3) hospital stays of less than 24&#160;h(<italic toggle="yes">n</italic>&#8201;=&#8201;10); (4) patients admitted to the hospital multiple times within a six-month period, we only include the first admission(<italic toggle="yes">n</italic>&#8201;=&#8201;15).</p><p id="Par40">Ultimately, this study enrolled a total of 585 patients, comprising 195 diagnosed with ALF and 390 with ACLF.</p></sec><sec id="Sec4"><title>Definitions</title><p id="Par41">Several key definitions in this study are outlined below.</p><p id="Par42">ALF is commonly defined as the onset of coagulopathy international normalized ratio (INR)&#8201;&#8805;&#8201;1.5 and encephalopathy (any degree of altered mentation) in a patient without preexisting liver disease or cirrhosis and with an illness of up to 4 weeks duration [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par43">The revised Asian Pacific Association for the Study of the Liver (APASL) consensus defines ACLF as an acute hepatic insult, characterized by jaundice (serum bilirubin&#8201;&#8805;&#8201;85 &#181;mol/L) and coagulopathy (INR&#8201;&#8805;&#8201;1.5 or prothrombin activity&#8201;&lt;&#8201;40%), complicated within 4 weeks by clinically detected ascites and/or encephalopathy, in a patient with or without a previous diagnosis of chronic liver disease or cirrhosis, and associated with a high 28-day mortality [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par44">MODS is defined as the concurrent dysfunction of two or more organ systems, including neurological, cardiovascular, respiratory, hematological, renal, hepatic. It is well-established that an increase in the number of failing organ systems correlates with a higher risk of patient mortality. MODS represents one of the leading causes of morbidity and mortality among critically ill patients admitted to intensive care units (ICUs) globally [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par45">Sepsisdefinition: Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Clinical criteria for sepsis include suspected or documented infection and an acute increase of &#8805;&#8201;2 Sequential Organ Failure Assessment (SOFA) points [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par46">Acute kidney injury (AKI) was diagnosed based on the following criteria: an increase in serum creatinine (Scr) by &#8805;&#8201;0.3&#160;mg/dL within 48&#160;h, an elevation of 1.5 to 2 fold relative to the baseline level, or the presence of oliguria (urine output&#8201;&lt;&#8201;0.5&#160;ml/kg/h for &#8805;&#8201;6&#160;h) [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par47">Respiratory failure is defined by a partial pressure of arterial oxygen to FiO<sub>2</sub> ratio (PaO<sub>2</sub>/FiO<sub>2</sub>)&#8201;&#8804;&#8201;200, consistent with the SOFA score criteria, or an SpO<sub>2</sub> to FiO<sub>2</sub> ratio&#8201;&#8804;&#8201;200.</p><p id="Par48">Circulatory failure is characterized by the presence of shock, defined as a mean arterial pressure (MAP)&#8201;&lt;&#8201;60 mmHg or a reduction of &#8805;&#8201;40 mmHg in systolic blood pressure from baseline, despite adequate fluid resuscitation and cardiac output.</p><p id="Par49">Coagulation failure is defined by an INR&#8201;&#8805;&#8201;1.5 or a prothrombin time (PT)&#8201;&lt;&#8201;40%. Since coagulation abnormalities are integral to the diagnosis of liver failure, we defined coagulation failure as persistent coagulation dysfunction that did not improve following administration of vitamin K1.</p><p id="Par50">Cerebral failure is indicated by changes in behavior and minimal alterations in the level of consciousness, signaling the need for early intervention in patients with hepatic encephalopathy (HE). Cerebral failure is defined by grade III or IV HE [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par51">Electrolyte imbalance is defined as the presence of any one or more of the following four conditions: (1)serum sodium concentration&#8201;&lt;&#8201;135 mmol/L or &gt;&#8201;145 mmol/L; (2)serum potassium&#8201;&lt;&#8201;3.5 mmol/L or &gt;&#8201;5.5mmol/L; (3)serum calcium&#8201;&gt;&#8201;2.5 mmol/L or &lt;&#8201;2.0 mmol/L; (4)serum magnesium&#8201;&lt;&#8201;0.65 mmol/L or &gt;&#8201;1.05 mmol/L [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec5"><title>Clinical data collection and follow up</title><p id="Par52">The collected data encompass demographics, ethnicity, biochemical parameters at admission, primary etiology of liver failure, admission precipitants, admission critical illness scores, and the worst critical illness scores.</p><p id="Par53">The status of MODS, number and categories of organ failures, clinical issues at admission, infections during hospitalization, organ support measures, and clinical outcomes.</p><p id="Par54">Patients were retrospectively followed up through a medical record system or telephone interviews. Mortality data accuracy was ensured by cross-referencing with the Registration Information System for National Medical Certificates of Death in China. Follow-up visits were conducted by hepatologists via telephone as part of this study.</p></sec><sec id="Sec6"><title>Statistical analysis methods</title><sec id="Sec7"><title>Descriptive statistics</title><p id="Par55">Patient baseline characteristics and other relevant data were summarized using medians (interquartile ranges) for continuous variables and percentages for categorical variables.&#8203;</p></sec><sec id="Sec8"><title>Inter-group comparisons</title><p id="Par56">Categorical variables were compared using the chi-squared test or Fisher&#8217;s exact test, while continuous variables were analyzed with the Student&#8217;s t-test or Mann&#8211;Whitney U test, depending on data distribution.&#8203;</p></sec><sec id="Sec9"><title>Risk factor analysis</title><p id="Par57">Variables showing statistical significance (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05) in univariate analysis were incorporated into a multivariate logistic regression model to identify independent risk factors associated with 90-day mortality.&#8203;</p></sec><sec id="Sec10"><title>Survival analysis</title><p id="Par58">Kaplan&#8211;Meier curves were generated to depict survival outcomes. The Cox proportional hazards model was applied to evaluate disparities in survival curves between ALF and ACLF patients, with the log-rank test used for statistical comparison of the curves.&#8203;</p><p id="Par59">A two-tailed <italic toggle="yes">p</italic>-value&#8201;&lt;&#8201;0.05 was deemed statistically significant. All statistical analyses were conducted using SPSS version 22.0 (SPSS, Inc., Chicago, IL, USA).</p></sec></sec><sec id="Sec11"><title>Ethical statement</title><p id="Par60"> This study adhered to the ethical standards outlined in the "Declaration of Helsinki" and the "Ethical Review of Biomedical Research Involving Humans". The research involved no interference with diagnosis or treatment; it utilized only observational data for analysis. </p><p id="Par61"> All patients had completed their treatments prior to the commencement of the study. Furthermore, patient privacy and data confidentiality were strictly respected and protected throughout the study. Given that there was no risk or harm to patients, the need for informed consent was waived by the Ethics Committee of Beijing Ditan Hospital, Capital Medical University. </p><p id="Par62"> The research protocol was reviewed and approved by the same committee, under reference number DTEC-KT2009-001-03.</p></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>Admission characteristics and the impact of MODS on prognosis between patients with ALF and ACLF</title><p id="Par63">Table&#160;<xref rid="Tab1" ref-type="table">1</xref> presents the enrollment details of our study, which included 195 patients with ALF and 390 patients with ACLF. The cohort was predominantly male (70.6%) with a median age of 51 years (interquartile range:40&#3934;60). Notably, ALF patients were significantly younger than ACLF patients. There was also a significant difference in the proportion of males between the two groups. <table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Characteristics,&#160;MODS and Prognosis in Patients with ALF Compared to Patients with ACLF</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="1" rowspan="1">All</th><th align="left" colspan="1" rowspan="1">ALF</th><th align="left" colspan="1" rowspan="1">ACLF</th><th align="left" rowspan="2" colspan="1"><italic toggle="yes">p</italic></th></tr><tr><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;585</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;195</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">n</italic>&#8201;=&#8201;390</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Demographics</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Age in years, median (IQR)</td><td align="left" colspan="1" rowspan="1">51 (40&#8211;60)</td><td align="left" colspan="1" rowspan="1">47 (29&#8211;60)</td><td align="left" colspan="1" rowspan="1">53 (44&#8211;61)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">413 (70.6%)</td><td align="left" colspan="1" rowspan="1">116 (59.5%)</td><td align="left" colspan="1" rowspan="1">297 (76.2%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;BMI, median (IQR)</td><td align="left" colspan="1" rowspan="1">22.50 (20.90&#8211;24.54)</td><td align="left" colspan="1" rowspan="1">22.72 (20.90&#8211;24.61)</td><td align="left" colspan="1" rowspan="1">22.35 (20.81&#8211;24.47)</td><td align="left" colspan="1" rowspan="1">0.626</td></tr><tr><td align="left" colspan="5" rowspan="1">Ethnicity</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Han, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">564 (96.4%)</td><td align="left" colspan="1" rowspan="1">189 (96.9%)</td><td align="left" colspan="1" rowspan="1">375 (96.2%)</td><td align="left" colspan="1" rowspan="1">0.637</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Manchu, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">13 (2.2%)</td><td align="left" colspan="1" rowspan="1">5(2.6%)</td><td align="left" colspan="1" rowspan="1">8 (2%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mongol, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">2 (0.3%)</td><td align="left" colspan="1" rowspan="1">1 (0.5%)</td><td align="left" colspan="1" rowspan="1">1 (0.26%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Tibetan, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">1 (0.17%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (0.26%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hui, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">4 (0.7%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">4 (1%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Zhuang, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">1 (0.17%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (0.26%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">Biochemistry at admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ALT (U/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">184.7(50&#8211;894)</td><td align="left" colspan="1" rowspan="1">1302.3(377.8-2727.5)</td><td align="left" colspan="1" rowspan="1">85.2(32.2-329.6)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AST (U/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">208(75-693.4)</td><td align="left" colspan="1" rowspan="1">714.7(277.7-2033.2)</td><td align="left" colspan="1" rowspan="1">125.3(56.3-351.6)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;CHE (U/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">3041(2000&#8211;4259)</td><td align="left" colspan="1" rowspan="1">3935(2994&#8211;5290)</td><td align="left" colspan="1" rowspan="1">2575(1809&#8211;3709)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Tbil(&#181;mol/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">197.2 (108.0&#8211;320.7)</td><td align="left" colspan="1" rowspan="1">213.5 (125.1&#8211;324.2)</td><td align="left" colspan="1" rowspan="1">187.4(96.9&#8211;313.9.1)</td><td align="left" colspan="1" rowspan="1">0.056</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;NH<sub>3</sub> (&#181;mol/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">34 (28&#8211;45)</td><td align="left" colspan="1" rowspan="1">43 (32&#8211;59)</td><td align="left" colspan="1" rowspan="1">33(27&#8211;40)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Creatinine (&#181;mol/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">69.8 (58.9&#8211;92.8)</td><td align="left" colspan="1" rowspan="1">67.8 (54.7&#8211;100.3)</td><td align="left" colspan="1" rowspan="1">70.7 (60.3&#8211;89.4)</td><td align="left" colspan="1" rowspan="1">0.334</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;INR, median (IQR)</td><td align="left" colspan="1" rowspan="1">2.13 (1.76&#8211;2.88)</td><td align="left" colspan="1" rowspan="1">2.59(1.80&#8211;4.19)</td><td align="left" colspan="1" rowspan="1">2.02(1.73&#8211;2.51)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Platelets count(&#215; 109/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">110 (69&#8211;160)</td><td align="left" colspan="1" rowspan="1">141.4 (94&#8211;183)</td><td align="left" colspan="1" rowspan="1">94 (59&#8211;148)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Albumin (g/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">30.9 (27.5&#8211;34.7)</td><td align="left" colspan="1" rowspan="1">33 (29.2&#8211;37.1)</td><td align="left" colspan="1" rowspan="1">30.3(26.7&#8211;33.1)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Leucocytes(&#215;109/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">6.22 (4.61&#8211;9.18)</td><td align="left" colspan="1" rowspan="1">7.72 (5.85&#8211;11.74)</td><td align="left" colspan="1" rowspan="1">5.63 (4.08&#8211;8.0)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neutrophil(&#215;109/L), median (IQR)</td><td align="left" colspan="1" rowspan="1">4.24(2.76&#8211;6.60)</td><td align="left" colspan="1" rowspan="1">5.38(3.61&#8211;7.95)</td><td align="left" colspan="1" rowspan="1">3.69(2.42&#8211;5.90)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;NLR, median (IQR)</td><td align="left" colspan="1" rowspan="1">3.63(2.18&#8211;6.25)</td><td align="left" colspan="1" rowspan="1">3.82(2.33&#8211;6.07)</td><td align="left" colspan="1" rowspan="1">3.56 (2.11&#8211;6.43)</td><td align="left" colspan="1" rowspan="1">0.704</td></tr><tr><td align="left" colspan="5" rowspan="1">Primary etiology of liver failure</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;HBV, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">299 (51.1%)</td><td align="left" colspan="1" rowspan="1">51 (26.2%)</td><td align="left" colspan="1" rowspan="1">248 (63.6%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;HCV, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">8 (1.4%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">8 (2.1%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;HEV, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">33 (5.6%)</td><td align="left" colspan="1" rowspan="1">28 (14.4%)</td><td align="left" colspan="1" rowspan="1">5 (1.3%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Drug-induced, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">79 (13.5%)</td><td align="left" colspan="1" rowspan="1">67(34.4%)</td><td align="left" colspan="1" rowspan="1">12 (3.1%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AIH, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">36 (6.2%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">36 (9.2%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Alcohol consumption, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">67(11.5%)</td><td align="left" colspan="1" rowspan="1">3 (1.5%)</td><td align="left" colspan="1" rowspan="1">64 (16.4%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">63(10.8%)</td><td align="left" colspan="1" rowspan="1">46 (23.6%)</td><td align="left" colspan="1" rowspan="1">17 (4.4%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cirrhosis, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">294 (50.3%)</td><td align="left" colspan="1" rowspan="1">&#8212;</td><td align="left" colspan="1" rowspan="1">294 (75.4%)</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="5" rowspan="1">Admission critical illness score</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Admission MELD, median (IQR)</td><td align="left" colspan="1" rowspan="1">24 (20&#8211;30)</td><td align="left" colspan="1" rowspan="1">28 (23&#8211;33)</td><td align="left" colspan="1" rowspan="1">23 (19&#8211;28)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Admission MELD-Na, median (IQR)</td><td align="left" colspan="1" rowspan="1">26 (21&#8211;32)</td><td align="left" colspan="1" rowspan="1">30 (23&#8211;37)</td><td align="left" colspan="1" rowspan="1">23 (19&#8211;30)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Admission CLIF-SOFA, median (IQR)</td><td align="left" colspan="1" rowspan="1">6 (4&#8211;9)</td><td align="left" colspan="1" rowspan="1">7 (5&#8211;14)</td><td align="left" colspan="1" rowspan="1">5 (3&#8211;8)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Admission SOFA, median (IQR)</td><td align="left" colspan="1" rowspan="1">7 (5&#8211;10)</td><td align="left" colspan="1" rowspan="1">8 (6&#8211;15)</td><td align="left" colspan="1" rowspan="1">6 (5&#8211;9)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Admission APACHE-II, median (IQR)</td><td align="left" colspan="1" rowspan="1">15 (10&#8211;21)</td><td align="left" colspan="1" rowspan="1">19 (14&#8211;28)</td><td align="left" colspan="1" rowspan="1">12 (10&#8211;18)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="5" rowspan="1">Worst critical illness score</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Peak MELD, median (IQR)</td><td align="left" colspan="1" rowspan="1">26 (21&#8211;33)</td><td align="left" colspan="1" rowspan="1">31 (25&#8211;41)</td><td align="left" colspan="1" rowspan="1">24 (20&#8211;30)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Peak MELD-Na, median (IQR)</td><td align="left" colspan="1" rowspan="1">29(23&#8211;38)</td><td align="left" colspan="1" rowspan="1">35 (27&#8211;46)</td><td align="left" colspan="1" rowspan="1">26 (21&#8211;34)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;MODS, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">295(50.4%)</td><td align="left" colspan="1" rowspan="1">119(61%)</td><td align="left" colspan="1" rowspan="1">176(45.1%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Number of organ failures, median (IQR)</td><td align="left" colspan="1" rowspan="1">2 (1&#8211;2)</td><td align="left" colspan="1" rowspan="1">2(1&#8211;3)</td><td align="left" colspan="1" rowspan="1">1(1&#8211;2)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;0.001</bold></td></tr><tr><td align="left" colspan="5" rowspan="1">Categories of organ failures</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cerebral failure, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">238(40.7%)</td><td align="left" colspan="1" rowspan="1">93(47.7%)</td><td align="left" colspan="1" rowspan="1">145(37.2%)</td><td align="left" colspan="1" rowspan="1"><bold>0.016</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Circulatory Failure, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">100(17.1%)</td><td align="left" colspan="1" rowspan="1">34(17.4%)</td><td align="left" colspan="1" rowspan="1">66(16.9%)</td><td align="left" colspan="1" rowspan="1">0.907</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Coagulation failure, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">486(83.1%)</td><td align="left" colspan="1" rowspan="1">172(88.2%)</td><td align="left" colspan="1" rowspan="1">314(80.5%)</td><td align="left" colspan="1" rowspan="1"><bold>0.019</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;AKI, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">154 (26.3%)</td><td align="left" colspan="1" rowspan="1">63(32.3%)</td><td align="left" colspan="1" rowspan="1">91 (23.3%)</td><td align="left" colspan="1" rowspan="1">0.006&#8195;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Respiratory failure, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">115(19.7%)</td><td align="left" colspan="1" rowspan="1">52(26.7%)</td><td align="left" colspan="1" rowspan="1">63(16.2%)</td><td align="left" colspan="1" rowspan="1"><bold>0.022</bold></td></tr><tr><td align="left" colspan="5" rowspan="1">Clinical admission issues (may be &#8805;&#8201;1)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatic encephalopathy, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">357 (61%)</td><td align="left" colspan="1" rowspan="1">195 (100%)</td><td align="left" colspan="1" rowspan="1">162(41.5%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Sepsis, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">461 (78.8%)</td><td align="left" colspan="1" rowspan="1">157 (80.5%)</td><td align="left" colspan="1" rowspan="1">304(77.9%)</td><td align="left" colspan="1" rowspan="1">0.520</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Septic Shock, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">98(16.8%)</td><td align="left" colspan="1" rowspan="1">35(17.9%)</td><td align="left" colspan="1" rowspan="1">63(16.2%)</td><td align="left" colspan="1" rowspan="1">0.639</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Gastrointestinal bleed, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">100 (17.1%)</td><td align="left" colspan="1" rowspan="1">24 (12.3%)</td><td align="left" colspan="1" rowspan="1">76(19.5%)</td><td align="left" colspan="1" rowspan="1"><bold>0.036</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatic ascites, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">405(69.2%)</td><td align="left" colspan="1" rowspan="1">55(28.2%)</td><td align="left" colspan="1" rowspan="1">350(89.7%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hepatic hydrothorax, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">116(19.8%)</td><td align="left" colspan="1" rowspan="1">29(14.9%)</td><td align="left" colspan="1" rowspan="1">87(22.3%)</td><td align="left" colspan="1" rowspan="1"><bold>0.037</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Electrolyte imbalance, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">354 (60.5%)</td><td align="left" colspan="1" rowspan="1">84 (43.1%)</td><td align="left" colspan="1" rowspan="1">270 (69.2%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="5" rowspan="1">Infections during at hospital</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;SBP <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">267 (45.6%)</td><td align="left" colspan="1" rowspan="1">66 (33.8%)</td><td align="left" colspan="1" rowspan="1">201 (51.5%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Pneumonia <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">202 (34.5%)</td><td align="left" colspan="1" rowspan="1">81 (41.5%)</td><td align="left" colspan="1" rowspan="1">121 (31%)</td><td align="left" colspan="1" rowspan="1"><bold>0.013</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Urosepsis <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">18 (3.1%)</td><td align="left" colspan="1" rowspan="1">7 (3.6%)</td><td align="left" colspan="1" rowspan="1">11 (2.8%)</td><td align="left" colspan="1" rowspan="1">0.618</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Biliary <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">131 (22.4%)</td><td align="left" colspan="1" rowspan="1">42(21.5%)</td><td align="left" colspan="1" rowspan="1">89 (22.8%)</td><td align="left" colspan="1" rowspan="1">0.753</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other infections <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">70 (12%)</td><td align="left" colspan="1" rowspan="1">23 (11.8%)</td><td align="left" colspan="1" rowspan="1">47 (12.1%)</td><td align="left" colspan="1" rowspan="1">0.928</td></tr><tr><td align="left" colspan="5" rowspan="1">Organ support</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;ICU admission, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">122 (20.9%)</td><td align="left" colspan="1" rowspan="1">79 (40.5%)</td><td align="left" colspan="1" rowspan="1">43(11%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Needing CRRT, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">57 (9.7%)</td><td align="left" colspan="1" rowspan="1">35(17.9%)</td><td align="left" colspan="1" rowspan="1">22 (5.6%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Needing MV <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">74(12.6%)</td><td align="left" colspan="1" rowspan="1">46 (23.6%)</td><td align="left" colspan="1" rowspan="1">28 (7.2%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="5" rowspan="1">Clinical outcomes</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Received LT, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">25 (4.3%)</td><td align="left" colspan="1" rowspan="1">17(8.7%)</td><td align="left" colspan="1" rowspan="1">8 (2.1%)</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Died during at hospital, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">90 (15.4%)</td><td align="left" colspan="1" rowspan="1">40 (20.5%)</td><td align="left" colspan="1" rowspan="1">50(12.8%)</td><td align="left" colspan="1" rowspan="1"><bold>0.02</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Death within 28&#8201;d, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">127(21.7%)</td><td align="left" colspan="1" rowspan="1">58(29.7%)</td><td align="left" colspan="1" rowspan="1">69(17.7%)</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Death within 90&#8201;d, <italic toggle="yes">n</italic> (%)</td><td align="left" colspan="1" rowspan="1">167(28.5%)</td><td align="left" colspan="1" rowspan="1">66 (33.8%)</td><td align="left" colspan="1" rowspan="1">101(25.9%)</td><td align="left" colspan="1" rowspan="1">0.052</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ALF</italic> Acute liver failure,&#160;<italic toggle="yes">ACLF</italic> Acute on chronic liver failure,&#160;<italic toggle="yes">IQR</italic> Interquartile range, <italic toggle="yes">BMI</italic> Body mass index, <italic toggle="yes">ALT</italic> Alanine transaminase, <italic toggle="yes">AST</italic> Aspartate transaminase, <italic toggle="yes">CHE</italic> Cholinesterase,&#160;<italic toggle="yes">Tbil</italic> Total bilirubin,&#160;<italic toggle="yes">INR</italic> International normalized ratio,&#160;<italic toggle="yes">NLR</italic> Neutrophil/lymphocyte ratio,&#160;<italic toggle="yes">HBV</italic> Hepatitis B virus,&#160;<italic toggle="yes">HCV</italic> Hepatitis C virus, <italic toggle="yes">HEV</italic> Hepatitis E virus,&#160;<italic toggle="yes">AIH</italic> Autoimmune hepatitis,&#160;<italic toggle="yes">MELD</italic> Model for end-stage liver disease,&#160;<italic toggle="yes">CLIF-SOFA</italic> Chronic liver failure sequential organ failure assessment,&#160;<italic toggle="yes">SOFA</italic> sequential organ failure assessment,&#160;<italic toggle="yes">APACHE II</italic> Acute physiology and chronic health evaluation II.<italic toggle="yes">MODS</italic> Multiple organ distress syndrome, <italic toggle="yes">AKI</italic> Acute kidney injury, <italic toggle="yes">SBP</italic> Spontaneous bacterial peritonitis, <italic toggle="yes">ICU</italic> Intensive care unit,&#160;<italic toggle="yes">CRRT</italic> Continuous renal replacement therapy,&#160;<italic toggle="yes">MV</italic> Mechanical ventilation, <italic toggle="yes">LT</italic> Liver transplantation</p><p><italic toggle="yes">p </italic>value&#8201;&lt;&#8201;0.05 was considered significant and is highlighted in bold</p></table-wrap-foot></table-wrap></p><p id="Par64">The majority of participants identified as Han Chinese. In terms of etiology, drug-induced liver injury was the most common cause of liver failure in ALF patients (67, 34.4%), followed by hepatitis B virus (HBV) infection (51, 26.2%). In contrast, HBV infection was the leading cause among ACLF patients (248, 63.6%), followed by alcohol-associated liver disease (64, 16.4%).</p><p id="Par65">Compared to ACLF patients, ALF patients exhibited higher median admission levels for alanine transaminase (ALT), aspartate transaminase (AST), cholinesterase (CHE), NH<sub>3</sub>, INR, platelet count, albumin, leukocytes, and neutrophils. Additionally, ALF patients had higher median admission scores for model for end-stage liver disease (MELD), MELD-Na, SOFA, chronic liver failure (CLIF)-SOFA, and acute physiology and chronic health evaluation II (APACHE-II).</p><p id="Par66">Moreover, ALF patients tended to have higher peak MELD and MELD-Na scores during hospitalization.</p><p id="Par67">As shown in Table <xref rid="Tab1" ref-type="table">1</xref>, MODS occurred in 119 (61%) patients with ALF and 176 (45.1%) patients with ACLF. Patients with ALF exhibited a significantly higher number of organ failures compared to those with ACLF.</p><p id="Par68"> Regarding clinical admission issues, ACLF patients had a higher incidence of ascites during hospitalization. Additionally, ALF patients were more frequently admitted to the ICU compared to ACLF patients. </p><p id="Par69"> Significant differences were observed in infection sites: ALF patients had a higher incidence of pneumonia, while ACLF patients demonstrated a higher incidence of spontaneous bacterial peritonitis (SBP) during hospitalization. </p><p id="Par70"> Compared to ACLF patients, those with ALF exhibited higher in-hospital mortality and 28-day mortality rates. Moreover, ALF patients were more likely to require continuous renal replacement therapy (CRRT) and mechanical ventilation (MV).</p></sec><sec id="Sec14"><title>The comparison of 90-day survival rates among distinct cohorts</title><p id="Par71">Through Kaplan-Meier survival hazards analysis, we compared the cumulative 90-day mortality rates among patients with ALF and ACLF as illustrated in Fig.<xref rid="Fig1" ref-type="fig">1</xref>. This analysis revealed that patients with ALF had a significantly higher cumulative 90-day mortality rate (33.8% vs. 25.9%)compared to those with ACLF (&#967;2= 6.776,<italic toggle="yes">p</italic>= 0.009).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The Kaplan-Meier survival curves for 90-day survival in the ACLF and ALF groups</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12876_2025_4234_Fig1_HTML.jpg"/></fig></p><p id="Par72">Table <xref rid="Tab2" ref-type="table">2</xref>&#160;demonstrates the association between 90-day mortality and potential risk factors in patients with ACLF, as determined by univariate and multivariate logistic analyses.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>90-day mortality predictors in patients with ACLF</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" colspan="3" rowspan="1">Univariate</th><th align="left" colspan="3" rowspan="1">Multivariate</th></tr><tr><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (per year increase)</td><td align="left" colspan="1" rowspan="1">1.038</td><td align="left" colspan="1" rowspan="1">1.018&#8211;1.058</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">1.036</td><td align="left" colspan="1" rowspan="1">1.008&#8211;1.064</td><td align="left" colspan="1" rowspan="1"><bold>0.012</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Tbil (per unit increase)</td><td align="left" colspan="1" rowspan="1">1.004</td><td align="left" colspan="1" rowspan="1">1.003&#8211;1.006</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">1.004</td><td align="left" colspan="1" rowspan="1">1.002&#8211;1.006</td><td align="left" colspan="1" rowspan="1"><bold>0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">NH<sub>3</sub> (per unit increase)</td><td align="left" colspan="1" rowspan="1">1.033</td><td align="left" colspan="1" rowspan="1">1.015&#8211;1.05</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">1.009</td><td align="left" colspan="1" rowspan="1">0.983&#8211;1.036</td><td align="left" colspan="1" rowspan="1">0.512</td></tr><tr><td align="left" colspan="1" rowspan="1">INR (per unit increase)</td><td align="left" colspan="1" rowspan="1">1.596</td><td align="left" colspan="1" rowspan="1">1.228&#8211;2.073</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">0.981</td><td align="left" colspan="1" rowspan="1">0.664&#8211;1.451</td><td align="left" colspan="1" rowspan="1">0.942</td></tr><tr><td align="left" colspan="1" rowspan="1">CHE (per unit increase)</td><td align="left" colspan="1" rowspan="1">1.00</td><td align="left" colspan="1" rowspan="1">0.999-1.00</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">1.0</td><td align="left" colspan="1" rowspan="1">0.999-1.00</td><td align="left" colspan="1" rowspan="1"><bold>0.042</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">NLR (per unit increase)</td><td align="left" colspan="1" rowspan="1">1.16</td><td align="left" colspan="1" rowspan="1">1.103&#8211;1.221</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">1.074</td><td align="left" colspan="1" rowspan="1">1.027&#8211;1.122</td><td align="left" colspan="1" rowspan="1"><bold>0.002</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Number of organ failures(per unit increase)</td><td align="left" colspan="1" rowspan="1">1.254</td><td align="left" colspan="1" rowspan="1">1.052&#8211;1.495</td><td align="left" colspan="1" rowspan="1"><bold>0.011</bold></td><td align="left" colspan="1" rowspan="1">1.142</td><td align="left" colspan="1" rowspan="1">0.885&#8211;1.475</td><td align="left" colspan="1" rowspan="1">0.308</td></tr><tr><td align="left" colspan="1" rowspan="1">AKI (vs. no AKI)</td><td align="left" colspan="1" rowspan="1">7.825</td><td align="left" colspan="1" rowspan="1">4.645&#8211;13.182</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">1.278</td><td align="left" colspan="1" rowspan="1">0.602&#8211;2.715</td><td align="left" colspan="1" rowspan="1">0.523</td></tr><tr><td align="left" colspan="1" rowspan="1">GIB (vs. no GIB)</td><td align="left" colspan="1" rowspan="1">6.688</td><td align="left" colspan="1" rowspan="1">3.893&#8211;11.489</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">3.677</td><td align="left" colspan="1" rowspan="1">1.771&#8211;7.633</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">ICU admission (vs. no ICU admission)</td><td align="left" colspan="1" rowspan="1">13.54</td><td align="left" colspan="1" rowspan="1">6.36-28.822</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">2.476</td><td align="left" colspan="1" rowspan="1">0.771&#8211;7.949</td><td align="left" colspan="1" rowspan="1">0.128</td></tr><tr><td align="left" colspan="1" rowspan="1">MV(vs. no MV)</td><td align="left" colspan="1" rowspan="1">105.81</td><td align="left" colspan="1" rowspan="1">14.049-786</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">36.721</td><td align="left" colspan="1" rowspan="1">3.369-400.281</td><td align="left" colspan="1" rowspan="1"><bold>0.003</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">SBP (vs. no SBP)</td><td align="left" colspan="1" rowspan="1">3.732</td><td align="left" colspan="1" rowspan="1">2.257&#8211;6.171</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">2.546</td><td align="left" colspan="1" rowspan="1">1.281&#8211;5.06</td><td align="left" colspan="1" rowspan="1"><bold>0.008</bold></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ACLF</italic> Acute on chronic liver failure,&#160;<italic toggle="yes">Tbil</italic> Total bilirubin,&#160;<italic toggle="yes">INR</italic> International normalized ratio,&#160;<italic toggle="yes">CHE</italic> Cholinesterase,&#160;<italic toggle="yes">NLR</italic> Neutrophil/lymphocyte ratio,&#160;<italic toggle="yes">AKI</italic> Acute kidney injury,&#160;<italic toggle="yes">GIB</italic> Gastrointestinal bleeding,&#160;<italic toggle="yes">ICU</italic> Intensive care unit,&#160;<italic toggle="yes">MV</italic> Mechanical ventilation,&#160;<italic toggle="yes">SBP</italic> Spontaneous bacterial peritonitis</p><p><italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.05 was considered significant and is highlighted in bold</p></table-wrap-foot></table-wrap></p><p id="Par73">The results indicated that Age, Tbil, NH<sub>3</sub>,INR, CHE, neutrophil-to-lymphocyte ratio(NLR), number of organ failures, AKI, gastrointestinal bleeding(GIB), ICU admission, MV, SBPwere significant predictors of 90-day mortality. Multivariate analysis further revealed that Age, Tbil, CHE, NLR, GIB, SBP, and MV were independent significant predictors.By establishing a model, Logistics&#8201;=&#8201;0.035 * Age&#8201;+&#8201;0.004* Tbil&#8201;+&#8201;0.071*NLR&#8201;+&#8201;1.302*GIB&#8201;+&#8201;3.603*MV&#8201;+&#8201;0.935*SBP-5.365.</p><p id="Par74">Figure&#160;<xref rid="Fig2" ref-type="fig">2</xref>&#160;demonstrates that the area under the curve (AUC) of the logistic regression model was 0.893, which is higher than that of the MELD-NA score (0.752) and the Clif-SOFA score (0.752).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The effectiveness logistics, MELDNA score, ClifSOFA score in predicting the 90-day mortality in patients with ACLF</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="12876_2025_4234_Fig2_HTML.jpg"/></fig></p><p id="Par75">Table&#160;<xref rid="Tab3" ref-type="table">3</xref>&#160;illustrates the association between 90-day mortality post-admission and potential risk factors in patients with ALF, as assessed through univariate and multivariate logistic analyses. The results indicated that Age, INR, number of organ failures, platelet count, AKI, respiratory failure, GIB, albumin levels, septic shock, ICU admission, pneumonia were significant predictors of 90-day mortality. Multivariate analysis further revealed that Age, number of organ failures, and albumin levels were independent predictive factors. By establishing a model, Logistics&#8201;=&#8201;0.025 * Age&#8201;+&#8201;0.668 * Number of organ failures &#8722;&#8201;0.993 *Alb &#8722;&#8201;0.207.</p><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>90-day Mortality Predictors in Patients with ALF</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" colspan="3" rowspan="1">Univariate</th><th align="left" colspan="3" rowspan="1">Multivariate</th></tr><tr><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (per year increase)</td><td align="left" colspan="1" rowspan="1">1.019</td><td align="left" colspan="1" rowspan="1">1.001&#8211;1.037</td><td align="left" colspan="1" rowspan="1">
<bold>0.033</bold>
</td><td align="left" colspan="1" rowspan="1">1.025</td><td align="left" colspan="1" rowspan="1">1.002&#8211;1.049</td><td align="left" colspan="1" rowspan="1">
<bold>0.034</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">INR (per unit increase)</td><td align="left" colspan="1" rowspan="1">1.283</td><td align="left" colspan="1" rowspan="1">1.091&#8211;1.510</td><td align="left" colspan="1" rowspan="1">
<bold>0.003</bold>
</td><td align="left" colspan="1" rowspan="1">1.063</td><td align="left" colspan="1" rowspan="1">0.864&#8211;1.308</td><td align="left" colspan="1" rowspan="1">0.564</td></tr><tr><td align="left" colspan="1" rowspan="1">NLR (per unit increase)</td><td align="left" colspan="1" rowspan="1">1.021</td><td align="left" colspan="1" rowspan="1">0.961&#8211;1.085</td><td align="left" colspan="1" rowspan="1">0.505</td><td align="left" colspan="1" rowspan="1">0.989</td><td align="left" colspan="1" rowspan="1">0.912&#8211;1.074</td><td align="left" colspan="1" rowspan="1">0.797</td></tr><tr><td align="left" colspan="1" rowspan="1">Number of organ failures(per unit increase)</td><td align="left" colspan="1" rowspan="1">2.204</td><td align="left" colspan="1" rowspan="1">1.694&#8211;2.868</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td><td align="left" colspan="1" rowspan="1">1.95</td><td align="left" colspan="1" rowspan="1">1.247-3.049-</td><td align="left" colspan="1" rowspan="1">
<bold>0.003</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelets count(per unit increase)</td><td align="left" colspan="1" rowspan="1">0.992</td><td align="left" colspan="1" rowspan="1">0.988&#8211;0.997</td><td align="left" colspan="1" rowspan="1">
<bold>0.003</bold>
</td><td align="left" colspan="1" rowspan="1">0.994</td><td align="left" colspan="1" rowspan="1">0.988-1.000</td><td align="left" colspan="1" rowspan="1">0.055</td></tr><tr><td align="left" colspan="1" rowspan="1">AKI (vs. no AKI)</td><td align="left" colspan="1" rowspan="1">5.646</td><td align="left" colspan="1" rowspan="1">2.933&#8211;10.868</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td><td align="left" colspan="1" rowspan="1">1.128</td><td align="left" colspan="1" rowspan="1">0.418&#8211;3.043</td><td align="left" colspan="1" rowspan="1">0.812</td></tr><tr><td align="left" colspan="1" rowspan="1">Respiratory failure(vs. no Respiratory failure)</td><td align="left" colspan="1" rowspan="1">4.555</td><td align="left" colspan="1" rowspan="1">2.325&#8211;8.923</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td><td align="left" colspan="1" rowspan="1">1.162</td><td align="left" colspan="1" rowspan="1">0.380&#8211;3.551</td><td align="left" colspan="1" rowspan="1">0.793</td></tr><tr><td align="left" colspan="1" rowspan="1">GIB (vs. no GIB)</td><td align="left" colspan="1" rowspan="1">6.047</td><td align="left" colspan="1" rowspan="1">2.361&#8211;15.488</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td><td align="left" colspan="1" rowspan="1">1.852</td><td align="left" colspan="1" rowspan="1">0.556&#8211;6.167</td><td align="left" colspan="1" rowspan="1">0.315</td></tr><tr><td align="left" colspan="1" rowspan="1">Alb (per unit increase)</td><td align="left" colspan="1" rowspan="1">0.907</td><td align="left" colspan="1" rowspan="1">0.856&#8211;0.961</td><td align="left" colspan="1" rowspan="1">
<bold>0.001</bold>
</td><td align="left" colspan="1" rowspan="1">0.925</td><td align="left" colspan="1" rowspan="1">0.858&#8211;0.998</td><td align="left" colspan="1" rowspan="1">
<bold>0.044</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Septic shock (vs. no septic shock)</td><td align="left" colspan="1" rowspan="1">7.256</td><td align="left" colspan="1" rowspan="1">3.213&#8211;16.388</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td><td align="left" colspan="1" rowspan="1">2.533</td><td align="left" colspan="1" rowspan="1">0.848&#8211;7.562</td><td align="left" colspan="1" rowspan="1">0.096</td></tr><tr><td align="left" colspan="1" rowspan="1">ICU admission (vs. no ICU admission</td><td align="left" colspan="1" rowspan="1">2.643</td><td align="left" colspan="1" rowspan="1">1.436&#8211;4.863</td><td align="left" colspan="1" rowspan="1">
<bold>0.002</bold>
</td><td align="left" colspan="1" rowspan="1">0.682</td><td align="left" colspan="1" rowspan="1">0.258&#8211;1.807</td><td align="left" colspan="1" rowspan="1">0.442</td></tr><tr><td align="left" colspan="1" rowspan="1">Pneumonia (vs. no Pneumonia)</td><td align="left" colspan="1" rowspan="1">2.714</td><td align="left" colspan="1" rowspan="1">1.475&#8211;4.996</td><td align="left" colspan="1" rowspan="1">
<bold>0.001</bold>
</td><td align="left" colspan="1" rowspan="1">0.904</td><td align="left" colspan="1" rowspan="1">0.385&#8211;2.121</td><td align="left" colspan="1" rowspan="1">0.816</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ALF</italic> Acute liver failure,<italic toggle="yes">Tbil</italic> Total bilirubin,<italic toggle="yes">INR</italic> International normalized ratio,<italic toggle="yes">NLR</italic> Neutrophil/lymphocyte ratio,<italic toggle="yes">AKI</italic> Acute kidney injury,<italic toggle="yes">GIB</italic> Gastrointestinal bleeding,<italic toggle="yes">ICU</italic> Intensive care unit</p><p><italic toggle="yes">p</italic> value&#8201;&lt;&#8201;0.05 was considered significant and is highlighted in bold</p></table-wrap-foot></table-wrap><p id="Par76">Figure&#160;<xref rid="Fig3" ref-type="fig">3</xref>&#160;demonstrates that the AUC of the logistic regression model was 0.840, which is higher than that of the MELD score (0.654) and the SOFA score (0.777).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>The effectiveness of logistics, MELD score, SOFA score in predicting the 90- day mortality in patients with ALF</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="12876_2025_4234_Fig3_HTML.jpg"/></fig></p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par77">In this study, drug-induced (34.4%) and HBV infection (26.2%) emerged as the predominant factors in patients with ALF, while HBV infection (63.6%) and alcohol-associated factors (16.4%) were identified as key contributors in patients with ACLF. These findings align with prior investigations.</p><p id="Par78"> In China, HBV remains a significant nationwide concern, affecting nearly 100 million individuals [<xref ref-type="bibr" rid="CR16">16</xref>]. HBV is the primary pathogen leading to ALF in mainland China and much of East Asia, while hepatitis E virus is endemic in India and Southeast Asian nations, causing self-limiting illness with a notable risk of ALF in pregnant women. The epidemiology of LF has undergone rapid changes over the past decade. However, recent data indicate a rising incidence of drug and herb-induced ALF across many countries.The frequency of ALF due to drug-induced liver injury (DILI) and other causes is escalating. DILI constitutes a major component of ALF in Western nations, whereas infectious, particularly viral, causes predominate elsewhere [<xref ref-type="bibr" rid="CR17">17</xref>]. Unlike the Western context, ALF resulting from paracetamol is uncommon, with herbs and traditional medicines being the most frequently implicated agents in China [<xref ref-type="bibr" rid="CR18">18</xref>]. Severe alcohol-related hepatitis ranks as the second common precipitating factor of ACLF in Western countries, accounting for 25%&#65374;40% of cases [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par79">Although numerous studies have investigated ALF and ACLF, there remains a paucity of research comparing their respective survival rates. Our study revealed that ALF patients experienced significantly higher in-hospital mortality 28-day mortality, compared to ACLF patients.</p><p id="Par80"> By analyzing previous literature on the definitions and critical illness scores associated with these conditions, we aimed to elucidate the underlying reasons. Prior studies have reported a hospital mortality rate of 40% for ALF patients [<xref ref-type="bibr" rid="CR19">19</xref>], with 28-day and 90-day mortality rates of 33% and 51%, respectively [<xref ref-type="bibr" rid="CR20">20</xref>]. In an Australian cohort, 28-day and 90-day liver transplant-free mortality rates were 22.6% and 55.0%, respectively [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par81"> ALF is often associated with multi-organ dysfunction, attributed to an overwhelming pro-inflammatory state resulting from massive hepatocellular damage and concurrent inflammatory response. Our analysis suggests that the severity of hepatocellular damage and pro-inflammatory response places ALF patients at a higher risk. As a result,ALF patients exhibited higher median critical illness scores compared to ACLF patients. This indicates a more severe clinical presentation and poorer prognosis among ALF patients. Additionally, we observed a higher incidence of MODS and greater number of organ failures among patients with ALF compared to those with ACLF, with percentages of 61% and 45.1%, respectively&#160;(<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Patients diagnosed with MODS necessitated organ support interventions such as CRRT, MV. This observation suggests a potential association between MODS and poor prognosis, likely due to the increased severity of organ dysfunction.Specifically, patients experiencing persistent failure of three organs face a substantial risk of death within 28 days (70&#3934;100%) and 90 days (80&#3934;100%) [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par82">Early recognition and referral of high-risk patients to specialized centers, coupled with prompt management of liver failure and its complications, may improve patient outcomes [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par83">
HE manifests as brain dysfunction resulting from liver insufficiency or portosystemic shunting. Patients with advanced HE exhibit a 35% mortality rate in the ICU [<xref ref-type="bibr" rid="CR25">25</xref>]. Elevated NH<sub>3</sub> levels, a known contributor to HE pathogenesis.The results of this study are consistent with those of previous studies, and NH<sub>3</sub> were higher in ALF patients compared to ACLF patients (43 vs. 33 &#181;mol/L, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001).</p><p id="Par84">AKI affects up to 50% of hospitalized patients with liver failure and serves as a strong predictor of poor short and long term survival [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Additionally, AKI increases the risk of respiratory failure due to pulmonary edema in patients exhibiting clinical signs of intravascular volume overload.</p><p id="Par85">The proportion of patients with ALF and ACLF diagnosed with septic shock was 17.9% and 16.2%, respectively. Patients with septic shock have an increased ICU and in-hospital mortality [<xref ref-type="bibr" rid="CR28">28</xref>]. Patients with septic shock exhibit a hyperdynamic circulation with decreased systemic vascular resistance, manifested by low arterial blood pressure and increased cardiac output. LF is potentially reversible, and with early attenuation of the acute precipitating event, liver reserve improves, fibrosis regresses, and portal pressure decreases [<xref ref-type="bibr" rid="CR29">29</xref>]. Early recognition of LF before the onset of sepsis and extrahepatic insults (such as renal, circulatory, and respiratory failure) is crucial to prioritize organ-specific interventions [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par86">Mortality rates among patients requiring MV can be as high as 49.6%, highlighting its association with poor prognosis. Moreover, respiratory failure requiring MV was associated with the highest 28-day mortality rate (83.7%) in LF patients [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par87">In this study, we found that the proportion of ALF and ACLF patients diagnosed with sepsis was 80.5% and 77.9%, respectively, indicating a high occurrence of sepsis in LF patients.</p><p id="Par88">LF is characterized by immune dysfunction and dysregulated immune cell activation, leading to an increased risk of bacterial infections in patients with liver failure [<xref ref-type="bibr" rid="CR31">31</xref>].Immune dysfunction is central to LF pathogenesis and is believed to contribute to its infectious complications and their adverse effects on patient survival [<xref ref-type="bibr" rid="CR32">32</xref>].These dysfunction ultimately lead to acquired immunodeficiency, impairing the host&#8217;s antimicrobial responses and increasing susceptibility to infections [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Monocytes and macrophages play a crucial role in disease pathogenesis in both ALF and ACLF, driving local inflammation, tissue repair, and systemic complications [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par89">Sepsis can precipitate the progression of LF [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The mortality rates of patients with cirrhosis requiring ICU admission for sepsis and septic shock was ranging from 60&#8211;76% [<xref ref-type="bibr" rid="CR37">37</xref>]. These patients also face a high risk (40%) of hospital infection with both bacterial and fungal pathogens, with up to a four-fold increase in mortality [<xref ref-type="bibr" rid="CR38">38</xref>]. Bacterial infections are among the most common triggers of LF, with reported rates of bacterial and fungal infections of up to 80% and 32%, respectively, in patients with ALF [<xref ref-type="bibr" rid="CR39">39</xref>]. SBP and pneumonia are the top two common infectious complications, often caused by multidrug-resistant organisms [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par90">The NLR serves as an indicator of systemic inflammation based on complete blood count values.Patients with ALF exhibited a higher median admission leucocyte count and a relatively higher median admission NLR. These levels were significantly higher than the normal values, indicating severe systemic inflammation.Multivariate logistic analysis in ACLF patients revealed that a higher NLR (OR&#8201;=&#8201;1.075, 95% CI 1.027&#8211;1.126, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) was associated with increased 90-day mortality.</p><p id="Par91">Neutrophil count experiences a substantial increase, followed by migration of these neutrophils to affected areas.Generally, neutrophil count in blood increases with the progression of inflammatory diseases.Consequently, lymphocyte count decreases due to immunosuppression. Moreover, the release of various anti-inflammatory cytokines into the bloodstream induces immunosuppression, leading to apoptosis of numerous lymphocytes [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par92">NLR increased with disease progression, particularly in inflammatory diseases, and this increase correlated with the development of certain diseases. These findings suggest that higher NLR values are independently associated with unfavorable clinical prognosis in patients with sepsis [<xref ref-type="bibr" rid="CR43">43</xref>]. Recent evidence supports the utilization of NLR as a biomarker for predicting 90-day mortality risk in ACLF patients [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>].</p><p id="Par93">Despite being considered a promising and cost-efficient method for predicting mortality in critically ill patients with cirrhosis, there is ongoing debate regarding the most accurate cutoff value associated with high risk of poor outcomes. One study indicated that the mean normal NLR for men and women were 1.63 and 1.66, respectively [<xref ref-type="bibr" rid="CR46">46</xref>]. Another study demonstrated that NLR&#8201;&#8805;&#8201;2.72 in stable outpatients with cirrhosis was linked to increased mortality [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par94">However, in some conditions such as cachexia, the count of neutrophil may not increase. As inflammation progresses, the lymphocyte count decreases. However, the decrease is relatively delayed and may not accurately reflect disease progression [<xref ref-type="bibr" rid="CR42">42</xref>]. These factors may explain why NLR did not significantly affect the 90-day mortality of ALF.</p><p id="Par95">LF is a dynamic, multisystem process characterized by multiple defects and abnormalities in both cellular and soluble components of the immune system. These defects ultimately result in acquired immunodeficiency, which impairs the host&#8217;s antimicrobial responses and increases susceptibility to infections&#160;[<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].Immune dysfunction is central to the pathogenesis of LF and is hypothesized to contribute to infectious complications and their adverse effects on patient survival [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par96"> In this study, 78.8% of LF patients were diagnosed with sepsis, indicating a relatively high prevalence.</p><p id="Par97"> Given the severe organ dysfunction and immunocompromised state in patients with LF, they are particularly vulnerable to sepsis, which can exacerbate organ failure [<xref ref-type="bibr" rid="CR49">49</xref>]. Any patient with confirmed infection should undergo a thorough evaluation for sepsis or septic shock, as well as for potential organ dysfunction.</p><p id="Par98"> The Sepsis-3 criteria should be employed respectively to assess these conditions. These evaluations are essential for identifying patients at increased risk of mortality who may require more intensive care interventions [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par99"> Consequently, early identification of LF and sepsis prior to the development of sepsis and extrahepatic insults, such as renal, circulatory, and respiratory failure, is crucial for prioritizing organ-specific interventions.</p><p id="Par100"> Our study had several limitations. Firstly, it is crucial to acknowledge that this study was conducted as a single-center investigation, which may restrict its generalizability to other settings. Secondly, retrospective studies are susceptible to selection bias. Thirdly, single-center studies often face challenges in adequately controlling for all potential confounding factors that may influence the outcomes.A limitation of this study is its longitudinal design spanning 13 years. Over this extended period, the implementation of different treatment protocols likely introduced confounding variables, thereby affecting the final outcomes to some degree.</p></sec><sec id="Sec16"><title>Conclusion</title><p id="Par101">Approximately 50% of liver failure patients progress to MODS, with ALF patients demonstrating a higher incidence of MODS and poorer 90-day prognoses.</p></sec><sec id="Sec17" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12876_2025_4234_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1.</p></caption></media></supplementary-material>
</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ALF</term><def><p id="Par5">Acute liver failure</p></def></def-item><def-item><term>ACLF</term><def><p id="Par6">Acute-on-chronic liver failure</p></def></def-item><def-item><term>MODS</term><def><p id="Par7">Multiple organ dysfunction syndrome</p></def></def-item><def-item><term>LF</term><def><p id="Par8">Liver failure</p></def></def-item><def-item><term>HIS</term><def><p id="Par9">Hospital Information System</p></def></def-item><def-item><term>INR</term><def><p id="Par10">International normalized ratio</p></def></def-item><def-item><term>APASL</term><def><p id="Par11">Asian Pacific Association for the Study of the Liver</p></def></def-item><def-item><term>ICUs</term><def><p id="Par12">Intensive care units</p></def></def-item><def-item><term>SOFA</term><def><p id="Par13">Sequential Organ Failure Assessment </p></def></def-item><def-item><term>AKI</term><def><p id="Par14">Acute kidney injury</p></def></def-item><def-item><term>MAP</term><def><p id="Par15">Mean arterial pressure</p></def></def-item><def-item><term>PT</term><def><p id="Par16">Prothrombin time</p></def></def-item><def-item><term>HE</term><def><p id="Par17">Hepatic encephalopathy</p></def></def-item><def-item><term>IQR</term><def><p id="Par18">Interquartile range</p></def></def-item><def-item><term>ORs</term><def><p id="Par19">Odds ratios</p></def></def-item><def-item><term>CIs</term><def><p id="Par20">Confidence intervals</p></def></def-item><def-item><term>HBV</term><def><p id="Par21">Hepatitis B virus</p></def></def-item><def-item><term>ALT</term><def><p id="Par22">Alanine transaminase</p></def></def-item><def-item><term>AST</term><def><p id="Par23">Aspartate transaminase</p></def></def-item><def-item><term>CHE</term><def><p id="Par24">Cholinesterase</p></def></def-item><def-item><term>MELD</term><def><p id="Par25">Model for end-stage liver disease</p></def></def-item><def-item><term>CLIF</term><def><p id="Par26">Chronic liver failure </p></def></def-item><def-item><term>APACHE-II</term><def><p id="Par27">Acute physiology and chronic health evaluation II</p></def></def-item><def-item><term>SBP</term><def><p id="Par28">Spontaneous bacterial peritonitis</p></def></def-item><def-item><term>NLR</term><def><p id="Par29">Neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term>GIB</term><def><p id="Par30">Gastrointestinal bleeding</p></def></def-item><def-item><term>CRRT</term><def><p id="Par31">Continuous renal replacement therapy</p></def></def-item><def-item><term>MV</term><def><p id="Par32">Mechanical ventilation</p></def></def-item><def-item><term>DILI</term><def><p id="Par33">Drug-induced liver injury</p></def></def-item></def-list></glossary><fn-group><fn><p>Ang Li and Jingyuan Liu contributed equally to this work.</p></fn><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>AL and JYL mainly designed the research and offered the plan study ideas.HBG, NNY read the literature and collected medical records. HBG, AL and JYL were major contributors in writing the manuscript. The final manuscript was read and approved by all authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported, in part, by funding from theBeijing Research Ward Excellence Program, BRWEP2024W102170109 and the National clinical key specialty construction project and Capital health development research project,2023-NO.492.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Our data is available upon request. Please contact the correspondence author for access to the data.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par102">This study adhered to the ethical standards outlined in the &#8220;Declaration of Helsinki&#8221; and the &#8220;Ethical Review of Biomedical Research Involving Humans&#8221;. The research involved no interference with diagnosis or treatment; it utilized only observational data for analysis.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par103">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par104">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarin</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>M</given-names></name><name name-style="western"><surname>Eslam</surname><given-names>M</given-names></name><etal/></person-group><article-title>Liver diseases in the Asia-Pacific region: a lancet gastroenterology &amp; hepatology commission</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><issue>2</issue><fpage>167</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">31852635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(19)30342-5</pub-id><pub-id pub-id-type="pmcid">PMC7164809</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sarin S, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a lancet gastroenterology &amp; hepatology commission. Lancet Gastroenterol Hepatol. 2020;5(2):167&#8211;228.<pub-id pub-id-type="pmid">31852635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(19)30342-5</pub-id><pub-id pub-id-type="pmcid">PMC7164809</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trebicka</surname><given-names>J</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>J</given-names></name><name name-style="western"><surname>Papp</surname><given-names>M</given-names></name><etal/></person-group><article-title>PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis - ScienceDirect</article-title><source>J Hepatol</source><year>2021</year><volume>74</volume><issue>5</issue><fpage>1097</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">33227350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.11.019</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Trebicka J, Fernandez J, Papp M, et al. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis - ScienceDirect. J Hepatol. 2021;74(5):1097&#8211;108.<pub-id pub-id-type="pmid">33227350</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.11.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>State of the art&#8212;Artificial liver in China</article-title><source>Artif Organs</source><year>2019</year><volume>43</volume><issue>4</issue><fpage>336</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">30950079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/aor.13448</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Zhang Y, Li L. State of the art&#8212;Artificial liver in China. Artif Organs. 2019;43(4):336&#8211;41.<pub-id pub-id-type="pmid">30950079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/aor.13448</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wen-Yi</surname><given-names>G</given-names></name><name name-style="western"><surname>Bao-Yan</surname><given-names>X</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Acute-on-Chronic liver failure in china: rationale for developing a patient registry and baseline characteristics</article-title><source>Am J Epidemiol</source><year>2018</year><volume>187</volume><issue>9</issue><fpage>1829</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">29762630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwy083</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wen-Yi G, Bao-Yan X, Xin Z, et al. Acute-on-Chronic liver failure in china: rationale for developing a patient registry and baseline characteristics. Am J Epidemiol. 2018;187(9):1829&#8211;39.<pub-id pub-id-type="pmid">29762630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwy083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arroyo</surname><given-names>V</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>R</given-names></name><name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name><etal/></person-group><article-title>EASL-CLIF consortium CANONIC study. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis</article-title><source>J Hepatol</source><year>2015</year><volume>62</volume><issue>1 Suppl</issue><fpage>S131</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">25920082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2014.11.045</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Arroyo V, Moreau R, Jalan R, et al. EASL-CLIF consortium CANONIC study. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol. 2015;62(1 Suppl):S131&#8211;43.<pub-id pub-id-type="pmid">25920082</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2014.11.045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nanchal</surname><given-names>R</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>R</given-names></name><name name-style="western"><surname>Alhazzani</surname><given-names>W</given-names></name><etal/></person-group><article-title>Guidelines for the management of adult acute and acute-on-Chronic liver failure in the ICU: neurology, Peri-Transplant medicine, infectious disease, and gastroenterology considerations</article-title><source>Crit Care Med</source><year>2023</year><volume>51</volume><issue>5</issue><fpage>657</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">37052436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000005824</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Nanchal R, Subramanian R, Alhazzani W, et al. Guidelines for the management of adult acute and acute-on-Chronic liver failure in the ICU: neurology, Peri-Transplant medicine, infectious disease, and gastroenterology considerations. Crit Care Med. 2023;51(5):657&#8211;76.<pub-id pub-id-type="pmid">37052436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000005824</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernal</surname><given-names>W</given-names></name><name name-style="western"><surname>Wendon</surname><given-names>J</given-names></name></person-group><article-title>Acute liver failure</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>26</issue><fpage>2525</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">24369077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1208937</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369(26):2525&#8211;34.<pub-id pub-id-type="pmid">24369077</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1208937</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update</article-title><source>Hepatol Int</source><year>2019</year><volume>13</volume><issue>4</issue><fpage>353</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">31172417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-019-09946-3</pub-id><pub-id pub-id-type="pmcid">PMC6728300</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353&#8211;90.<pub-id pub-id-type="pmid">31172417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-019-09946-3</pub-id><pub-id pub-id-type="pmcid">PMC6728300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>RS</given-names></name><name name-style="western"><surname>Crow</surname><given-names>SS</given-names></name><name name-style="western"><surname>Hartman</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome (MODS)</article-title><source>Pediatr Crit Care Med</source><year>2017</year><volume>18</volume><issue>3suppl Suppl 1</issue><fpage>S4</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">28248829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PCC.0000000000001047</pub-id><pub-id pub-id-type="pmcid">PMC5334773</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Watson RS, Crow SS, Hartman ME, et al. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome (MODS). Pediatr Crit Care Med. 2017;18(3suppl Suppl 1):S4&#8211;16.<pub-id pub-id-type="pmid">28248829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PCC.0000000000001047</pub-id><pub-id pub-id-type="pmcid">PMC5334773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>SL</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>JC</given-names></name><name name-style="western"><surname>Pappachan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study</article-title><source>Am J Respir Crit Care Med</source><year>2015</year><volume>191</volume><issue>10</issue><fpage>1147</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">25734408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201412-2323OC</pub-id><pub-id pub-id-type="pmcid">PMC4451622</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Weiss SL, Fitzgerald JC, Pappachan J, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015;191(10):1147&#8211;57.<pub-id pub-id-type="pmid">25734408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.201412-2323OC</pub-id><pub-id pub-id-type="pmcid">PMC4451622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singer</surname><given-names>M</given-names></name><name name-style="western"><surname>Deutschman</surname><given-names>CS</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>CW</given-names></name><etal/></person-group><article-title>The third international consensus definitions for sepsis and septic shock (Sepsis-3)</article-title><source>JAMA</source><year>2016</year><volume>315</volume><issue>8</issue><fpage>775</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">26903338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmcid">PMC4968574</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):775&#8211;87.<pub-id pub-id-type="pmid">26903338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.0287</pub-id><pub-id pub-id-type="pmcid">PMC4968574</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khwaja</surname><given-names>A</given-names></name></person-group><article-title>KDIGO clinical practice guidelines for acute kidney injury</article-title><source>Nephron Clin Pract</source><year>2013</year><volume>120</volume><issue>4</issue><fpage>c179</fpage><lpage>184</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000339789</pub-id><pub-id pub-id-type="pmid">22890468</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2013;120(4):c179&#8211;184.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000339789</pub-id><pub-id pub-id-type="pmid">22890468</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sarin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Definition of ACLF and inclusion criteria for extra-hepatic organ failure</article-title><source>Hep Intl</source><year>2015</year><volume>9</volume><issue>3</issue><fpage>360</fpage><lpage>5</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-015-9637-x</pub-id><pub-id pub-id-type="pmid">26016465</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wang X, Sarin SK, Ning Q, et al. Definition of ACLF and inclusion criteria for extra-hepatic organ failure. Hep Intl. 2015;9(3):360&#8211;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-015-9637-x</pub-id><pub-id pub-id-type="pmid">26016465</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Juanola</surname><given-names>A</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>N</given-names></name><name name-style="western"><surname>Sol&#233;</surname><given-names>C</given-names></name><etal/></person-group><article-title>Organ dysfunction and failure in liver disease</article-title><source>Liver Int</source><year>2023</year><volume>45</volume><issue>3</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15622</pub-id><pub-id pub-id-type="pmid">37222263</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Juanola A, Tiwari N, Sol&#233; C, et al. Organ dysfunction and failure in liver disease. Liver Int. 2023;45(3):1&#8211;11.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15622</pub-id><pub-id pub-id-type="pmid">37222263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poe</surname><given-names>J</given-names></name><name name-style="western"><surname>Sriram</surname><given-names>S</given-names></name><name name-style="western"><surname>Mehkri</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Electrolyte imbalance and neurologic injury</article-title><source>CNS Neurol Disord Drug Target</source><year>2024</year><volume>23</volume><issue>7</issue><fpage>841</fpage><lpage>51</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871527322666230215144649</pub-id><pub-id pub-id-type="pmid">36790006</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Poe J, Sriram S, Mehkri Y, et al. Electrolyte imbalance and neurologic injury. CNS Neurol Disord Drug Target. 2024;23(7):841&#8211;51.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1871527322666230215144649</pub-id><pub-id pub-id-type="pmid">36790006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>FS</given-names></name><name name-style="western"><surname>Fan</surname><given-names>JG</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The global burden of liver disease: the major impact of China</article-title><source>Hepatology</source><year>2014</year><volume>60</volume><issue>6</issue><fpage>2099</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">25164003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.27406</pub-id><pub-id pub-id-type="pmcid">PMC4867229</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099&#8211;108.<pub-id pub-id-type="pmid">25164003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.27406</pub-id><pub-id pub-id-type="pmcid">PMC4867229</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goldberg</surname><given-names>DS</given-names></name><name name-style="western"><surname>Forde</surname><given-names>KA</given-names></name><name name-style="western"><surname>Carbonari</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Population-Representative Incidence of Drug-Induced Acute Liver Failure Based on an Analysis of an Integrated Health Care System</article-title><source>Gastroenterology.</source><year>2015</year><volume>148</volume><issue>7</issue><fpage>1353</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">25733099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2015.02.050</pub-id><pub-id pub-id-type="pmcid">PMC4446162</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Goldberg DS, Forde KA, Carbonari DM, et al. Population-Representative Incidence of Drug-Induced Acute Liver Failure Based on an Analysis of an Integrated Health Care System. Gastroenterology. 2015;148(7):1353&#8211;61.<pub-id pub-id-type="pmid">25733099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2015.02.050</pub-id><pub-id pub-id-type="pmcid">PMC4446162</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Causes and outcomes of acute liver failure in China</article-title><source>PLoS ONE</source><year>2015</year><volume>8</volume><issue>11</issue><fpage>e80991</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0080991</pub-id><pub-id pub-id-type="pmcid">PMC3838343</pub-id><pub-id pub-id-type="pmid">24278360</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Zhao P, Wang C, Liu W, et al. Causes and outcomes of acute liver failure in China. PLoS ONE. 2015;8(11):e80991.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0080991</pub-id><pub-id pub-id-type="pmcid">PMC3838343</pub-id><pub-id pub-id-type="pmid">24278360</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triantafyllou</surname><given-names>E</given-names></name><name name-style="western"><surname>Woollard</surname><given-names>KJ</given-names></name><name name-style="western"><surname>McPhail</surname><given-names>MJW</given-names></name><etal/></person-group><article-title>The role of monocytes and macrophages in acute and acute-on-Chronic liver failure</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">30619308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.02948</pub-id><pub-id pub-id-type="pmcid">PMC6302023</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Triantafyllou E, Woollard KJ, McPhail MJW, et al. The role of monocytes and macrophages in acute and acute-on-Chronic liver failure. Front Immunol. 2018;9(1):1&#8211;17.<pub-id pub-id-type="pmid">30619308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.02948</pub-id><pub-id pub-id-type="pmcid">PMC6302023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schulz</surname><given-names>MS</given-names></name><name name-style="western"><surname>Mengers</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Pulmonary impairment independently determines mortality in critically ill patients with acute-on-chronic liver failure</article-title><source>Liver Int</source><year>2023</year><volume>43</volume><issue>1</issue><fpage>180</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">35727853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15343</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Schulz MS, Mengers J, Gu W, et al. Pulmonary impairment independently determines mortality in critically ill patients with acute-on-chronic liver failure. Liver Int. 2023;43(1):180&#8211;93.<pub-id pub-id-type="pmid">35727853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15343</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chetwood</surname><given-names>JD</given-names></name><name name-style="western"><surname>Sabih</surname><given-names>A-H</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Epidemiology, characteristics, and outcomes of patients with acute-on&#8208;chronic liver failure in Australia</article-title><source>J Gastroenterol Hepatol</source><year>2023</year><volume>38</volume><issue>8</issue><fpage>1325</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">37096760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.16197</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chetwood JD, Sabih A-H, Chan K, et al. Epidemiology, characteristics, and outcomes of patients with acute-on&#8208;chronic liver failure in Australia. J Gastroenterol Hepatol. 2023;38(8):1325&#8211;32.<pub-id pub-id-type="pmid">37096760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jgh.16197</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karvellas</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Garcia-Lopez</surname><given-names>E</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dynamic prognostication in critically ill cirrhotic patients with multiorgan failure in ICUs in Europe and North america: A multicenter analysis</article-title><source>Crit Care Med</source><year>2018</year><volume>46</volume><issue>11</issue><fpage>1783</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">30106759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000003369</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Karvellas CJ, Garcia-Lopez E, Fernandez J, et al. Dynamic prognostication in critically ill cirrhotic patients with multiorgan failure in ICUs in Europe and North america: A multicenter analysis. Crit Care Med. 2018;46(11):1783&#8211;91.<pub-id pub-id-type="pmid">30106759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000003369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>R</given-names></name><name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name><name name-style="western"><surname>Gines</surname><given-names>P</given-names></name><etal/></person-group><article-title>Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis</article-title><source>Gastroenterology</source><year>2013</year><volume>144</volume><issue>7</issue><fpage>1426</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">23474284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2013.02.042</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426&#8211;37.<pub-id pub-id-type="pmid">23474284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2013.02.042</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reverter</surname><given-names>E</given-names></name><name name-style="western"><surname>Toapanta</surname><given-names>D</given-names></name><name name-style="western"><surname>Bassegoda</surname><given-names>O</given-names></name><etal/></person-group><article-title>Critical care management of acute-on-chronic liver failure: certainties and unknowns</article-title><source>Semin Liver Dis</source><year>2023</year><volume>43</volume><issue>2</issue><fpage>206</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">37369227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0043-1769907</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Reverter E, Toapanta D, Bassegoda O, et al. Critical care management of acute-on-chronic liver failure: certainties and unknowns. Semin Liver Dis. 2023;43(2):206&#8211;17.<pub-id pub-id-type="pmid">37369227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0043-1769907</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vilstrup</surname><given-names>H</given-names></name><name name-style="western"><surname>Amodio</surname><given-names>P</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study</article-title><source>Liver Hepatol</source><year>2014</year><volume>60</volume><issue>2</issue><fpage>715</fpage><lpage>35</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.27210</pub-id><pub-id pub-id-type="pmid">25042402</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the study of liver diseases and the European association for the study. Liver Hepatol. 2014;60(2):715&#8211;35.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.27210</pub-id><pub-id pub-id-type="pmid">25042402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernal</surname><given-names>W</given-names></name><name name-style="western"><surname>Karvellas</surname><given-names>C</given-names></name><name name-style="western"><surname>Saliba</surname><given-names>F</given-names></name><etal/></person-group><article-title>Intensive care management of acute-on-chronic liver failure</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><issue>Suppl 1</issue><fpage>S163</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">34039487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.10.024</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Bernal W, Karvellas C, Saliba F, et al. Intensive care management of acute-on-chronic liver failure. J Hepatol. 2021;75(Suppl 1):S163&#8211;77.<pub-id pub-id-type="pmid">34039487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.10.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velez</surname><given-names>JCQ</given-names></name><name name-style="western"><surname>Therapondos</surname><given-names>G</given-names></name><name name-style="western"><surname>Juncos</surname><given-names>LA</given-names></name></person-group><article-title>Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis</article-title><source>Nat Rev Nephrol</source><year>2020</year><volume>16</volume><issue>3</issue><fpage>137</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">31723234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-019-0218-4</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Velez JCQ, Therapondos G, Juncos LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. Nat Rev Nephrol. 2020;16(3):137&#8211;55.<pub-id pub-id-type="pmid">31723234</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-019-0218-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcphail</surname><given-names>MJW</given-names></name><name name-style="western"><surname>Parrott</surname><given-names>F</given-names></name><name name-style="western"><surname>Wendon</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Incidence and outcomes for patients with cirrhosis admitted to the united Kingdom critical care units</article-title><source>Crit Care Med</source><year>2018</year><volume>46</volume><issue>5</issue><fpage>705</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">29309369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000002961</pub-id><pub-id pub-id-type="pmcid">PMC5899891</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Mcphail MJW, Parrott F, Wendon JA, et al. Incidence and outcomes for patients with cirrhosis admitted to the united Kingdom critical care units. Crit Care Med. 2018;46(5):705&#8211;12.<pub-id pub-id-type="pmid">29309369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000002961</pub-id><pub-id pub-id-type="pmcid">PMC5899891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarin</surname><given-names>SK</given-names></name><name name-style="western"><surname>Kedarisetty</surname><given-names>CK</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL)</article-title><source>Hepatol Int</source><year>2014</year><volume>8</volume><issue>4</issue><fpage>453</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">26202751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-014-9580-2</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL). Hepatol Int. 2014;8(4):453&#8211;71.<pub-id pub-id-type="pmid">26202751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-014-9580-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhury</surname><given-names>A</given-names></name><name name-style="western"><surname>Jindal</surname><given-names>A</given-names></name><name name-style="western"><surname>Maiwall</surname><given-names>R</given-names></name><etal/></person-group><article-title>Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models</article-title><source>Hepatol Int</source><year>2017</year><volume>11</volume><issue>5</issue><fpage>461</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">28856540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-017-9816-z</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Choudhury A, Jindal A, Maiwall R, et al. Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models. Hepatol Int. 2017;11(5):461&#8211;71.<pub-id pub-id-type="pmid">28856540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12072-017-9816-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agust&#237;n</surname><given-names>A</given-names></name><name name-style="western"><surname>Margaret</surname><given-names>L</given-names></name><name name-style="western"><surname>Melchor</surname><given-names>&#193;</given-names></name></person-group><article-title>Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><issue>6</issue><fpage>1385</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">25135860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2014.08.010</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Agust&#237;n A, Margaret L, Melchor &#193;. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385&#8211;96.<pub-id pub-id-type="pmid">25135860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2014.08.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cl&#224;ria</surname><given-names>J</given-names></name><name name-style="western"><surname>Stauber</surname><given-names>RE</given-names></name><name name-style="western"><surname>Coenraad</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on&#8208;chronic liver failure</article-title><source>Hepatology</source><year>2016</year><volume>64</volume><issue>4</issue><fpage>1249</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">27483394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.28740</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Cl&#224;ria J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on&#8208;chronic liver failure. Hepatology. 2016;64(4):1249&#8211;64.<pub-id pub-id-type="pmid">27483394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.28740</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piano</surname><given-names>S</given-names></name><name name-style="western"><surname>Brocca</surname><given-names>A</given-names></name><name name-style="western"><surname>Mareso</surname><given-names>S</given-names></name><etal/></person-group><article-title>Infections complicating cirrhosis</article-title><source>Liver Int</source><year>2018</year><volume>38</volume><issue>Suppl 1</issue><fpage>126</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">29427501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.13645</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Piano S, Brocca A, Mareso S, et al. Infections complicating cirrhosis. Liver Int. 2018;38(Suppl 1):126&#8211;31.<pub-id pub-id-type="pmid">29427501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.13645</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernsmeier</surname><given-names>C</given-names></name><name name-style="western"><surname>Singanayagam</surname><given-names>A</given-names></name><name name-style="western"><surname>Patel</surname><given-names>VC</given-names></name><etal/></person-group><article-title>Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure</article-title><source>Immunotherapy</source><year>2015</year><volume>7</volume><issue>6</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">26065379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt.15.27</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Bernsmeier C, Singanayagam A, Patel VC, et al. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure. Immunotherapy. 2015;7(6):1&#8211;14.<pub-id pub-id-type="pmid">26065379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt.15.27</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>J</given-names></name><name name-style="western"><surname>Piano</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartoletti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Management of bacterial and fungal infections in cirrhosis: the MDRO challenge</article-title><source>J Hepatol</source><year>2021</year><volume>75</volume><issue>Suppl 1</issue><fpage>S101</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">34039482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.11.010</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Fern&#225;ndez J, Piano S, Bartoletti M, et al. Management of bacterial and fungal infections in cirrhosis: the MDRO challenge. J Hepatol. 2021;75(Suppl 1):S101&#8211;17.<pub-id pub-id-type="pmid">34039482</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.11.010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deulofeu</surname><given-names>C</given-names></name><name name-style="western"><surname>Reverter</surname><given-names>E</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis</article-title><source>Gut</source><year>2018</year><volume>67</volume><issue>10</issue><fpage>1870</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">28847867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2017-314240</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Deulofeu C, Reverter E, Mart&#237;nez J, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67(10):1870&#8211;80.<pub-id pub-id-type="pmid">28847867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2017-314240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galbois</surname><given-names>A</given-names></name><name name-style="western"><surname>Aegerter</surname><given-names>P</given-names></name><name name-style="western"><surname>Martel-Samb</surname><given-names>P</given-names></name><etal/></person-group><article-title>Improved prognosis of septic shock in patients with cirrhosis**</article-title><source>Crit Care Med</source><year>2014</year><volume>42</volume><issue>7</issue><fpage>1666</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">24732239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000000321</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Galbois A, Aegerter P, Martel-Samb P, et al. Improved prognosis of septic shock in patients with cirrhosis**. Crit Care Med. 2014;42(7):1666&#8211;75.<pub-id pub-id-type="pmid">24732239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0000000000000321</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arvaniti</surname><given-names>VD</given-names></name><name name-style="western"><surname>Amico</surname><given-names>G</given-names></name><name name-style="western"><surname>Fede</surname><given-names>G</given-names></name><etal/></person-group><article-title>Infections in patients with cirrhosis increase mortality Four-Fold and should be used in determining prognosis</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><issue>4</issue><fpage>1246</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">20558165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2010.06.019</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Arvaniti VD, Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality Four-Fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246&#8211;56.<pub-id pub-id-type="pmid">20558165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2010.06.019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belicard</surname><given-names>F</given-names></name><name name-style="western"><surname>Pinceaux</surname><given-names>K</given-names></name><name name-style="western"><surname>Le</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Bacterial and fungal infections: a frequent and deadly complication among critically ill acute liver failure patients</article-title><source>Infect Dis (Lond)</source><year>2023</year><volume>55</volume><issue>7</issue><fpage>480</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">37211670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/23744235.2023.2213326</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Belicard F, Pinceaux K, Le PE, et al. Bacterial and fungal infections: a frequent and deadly complication among critically ill acute liver failure patients. Infect Dis (Lond). 2023;55(7):480&#8211;9.<pub-id pub-id-type="pmid">37211670</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/23744235.2023.2213326</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karvellas</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Gustot</surname><given-names>T</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>J</given-names></name></person-group><article-title>Management of the acute on chronic liver failure in the intensive care unit</article-title><source>Liver Int</source><year>2025</year><volume>45</volume><issue>3</issue><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">37365997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15659</pub-id><pub-id pub-id-type="pmcid">PMC11815614</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Karvellas CJ, Gustot T, Fernandez J. Management of the acute on chronic liver failure in the intensive care unit. Liver Int. 2025;45(3):1&#8211;14.<pub-id pub-id-type="pmid">37365997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.15659</pub-id><pub-id pub-id-type="pmcid">PMC11815614</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angus</surname><given-names>DC</given-names></name><name name-style="western"><surname>Poll</surname><given-names>T</given-names></name></person-group><article-title>Severe sepsis and septic shock</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>9</issue><fpage>840</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">23984731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1208623</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Angus DC, Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840&#8211;51.<pub-id pub-id-type="pmid">23984731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1208623</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidal</surname><given-names>AC</given-names></name><name name-style="western"><surname>Howard</surname><given-names>LE</given-names></name><name name-style="western"><surname>De Hoedt</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database</article-title><source>Cancer Causes Control</source><year>2018</year><volume>29</volume><issue>6</issue><fpage>581</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">29663110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10552-018-1031-2</pub-id><pub-id pub-id-type="pmcid">PMC5940530</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Vidal AC, Howard LE, De Hoedt A, et al. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2018;29(6):581&#8211;8.<pub-id pub-id-type="pmid">29663110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10552-018-1031-2</pub-id><pub-id pub-id-type="pmcid">PMC5940530</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><etal/></person-group><article-title>The neutrophil-lymphocyte count ratio as a diagnostic marker for bacteraemia: A systematic review and meta-analysis</article-title><source>Am J Emerg Med</source><year>2018</year><volume>37</volume><issue>8</issue><fpage>1482</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30413366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2018.10.057</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Jiang J, Liu R, Yu X, et al. The neutrophil-lymphocyte count ratio as a diagnostic marker for bacteraemia: A systematic review and meta-analysis. Am J Emerg Med. 2018;37(8):1482&#8211;9.<pub-id pub-id-type="pmid">30413366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2018.10.057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>N</given-names></name><name name-style="western"><surname>Wittebole</surname><given-names>X</given-names></name><name name-style="western"><surname>Fleury</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Neutrophil-to-Lymphocyte ratio predicts death in Acute-on-Chronic liver failure patients admitted to the intensive care unit: A retrospective cohort study</article-title><source>Shock</source><year>2017</year><volume>49</volume><issue>4</issue><fpage>385</fpage><lpage>92</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000000993</pub-id><pub-id pub-id-type="pmcid">PMC5811234</pub-id><pub-id pub-id-type="pmid">28930918</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Moreau N, Wittebole X, Fleury Y, et al. Neutrophil-to-Lymphocyte ratio predicts death in Acute-on-Chronic liver failure patients admitted to the intensive care unit: A retrospective cohort study. Shock. 2017;49(4):385&#8211;92.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SHK.0000000000000993</pub-id><pub-id pub-id-type="pmcid">PMC5811234</pub-id><pub-id pub-id-type="pmid">28930918</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>T</given-names></name><etal/></person-group><article-title>Evaluation of prognostic values of inflammation-based makers in patients with HBV-related acute-on-chronic liver failure</article-title><source>Med (Baltim)</source><year>2018</year><volume>97</volume><issue>46</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000013324</pub-id><pub-id pub-id-type="pmcid">PMC6257482</pub-id><pub-id pub-id-type="pmid">30431619</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Cai J, Wang K, Han T, et al. Evaluation of prognostic values of inflammation-based makers in patients with HBV-related acute-on-chronic liver failure. Med (Baltim). 2018;97(46):1&#8211;10.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000013324</pub-id><pub-id pub-id-type="pmcid">PMC6257482</pub-id><pub-id pub-id-type="pmid">30431619</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>NY</given-names></name><name name-style="western"><surname>Na</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea</article-title><source>Med (Baltim)</source><year>2018</year><volume>97</volume><issue>26</issue><fpage>e11138</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000011138</pub-id><pub-id pub-id-type="pmcid">PMC6039688</pub-id><pub-id pub-id-type="pmid">29952958</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Lee JS, Kim NY, Na SH, et al. Reference values of neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, platelet-lymphocyte ratio, and mean platelet volume in healthy adults in South Korea. Med (Baltim). 2018;97(26):e11138.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000011138</pub-id><pub-id pub-id-type="pmcid">PMC6039688</pub-id><pub-id pub-id-type="pmid">29952958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biyik</surname><given-names>M</given-names></name><name name-style="western"><surname>Ucar</surname><given-names>R</given-names></name><name name-style="western"><surname>Solak</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Blood neutrophil-to-lymphocyte ratio independently predicts survival in patients with liver cirrhosis</article-title><source>Eur J Gastroenterol Hepatol</source><year>2013</year><volume>25</volume><issue>4</issue><fpage>435</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">23249602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MEG.0b013e32835c2af3</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Biyik M, Ucar R, Solak Y, et al. Blood neutrophil-to-lymphocyte ratio independently predicts survival in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2013;25(4):435&#8211;41.<pub-id pub-id-type="pmid">23249602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MEG.0b013e32835c2af3</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernsmeier</surname><given-names>C</given-names></name><name name-style="western"><surname>Pop</surname><given-names>OT</given-names></name><name name-style="western"><surname>Singanayagam</surname><given-names>A</given-names></name><etal/></person-group><article-title>Patients with Acute-on-Chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK</article-title><source>Gastroenterology</source><year>2015</year><volume>148</volume><issue>3</issue><fpage>603</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">25479139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.11.045</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Bernsmeier C, Pop OT, Singanayagam A, et al. Patients with Acute-on-Chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology. 2015;148(3):603&#8211;15.<pub-id pub-id-type="pmid">25479139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2014.11.045</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><etal/></person-group><article-title>Early diagnostic biomarkers of sepsis for patients with Acute-on-Chronic liver failure: A multicenter study</article-title><source>Infect Dis Ther</source><year>2021</year><volume>10</volume><issue>1</issue><fpage>281</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">33146854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40121-020-00362-x</pub-id><pub-id pub-id-type="pmcid">PMC7954994</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Chen J, Huang ZB, Li H, et al. Early diagnostic biomarkers of sepsis for patients with Acute-on-Chronic liver failure: A multicenter study. Infect Dis Ther. 2021;10(1):281&#8211;90.<pub-id pub-id-type="pmid">33146854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40121-020-00362-x</pub-id><pub-id pub-id-type="pmcid">PMC7954994</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piano</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartoletti</surname><given-names>M</given-names></name><name name-style="western"><surname>Tonon</surname><given-names>M</given-names></name><etal/></person-group><article-title>Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections</article-title><source>Gut</source><year>2017</year><volume>67</volume><issue>10</issue><fpage>1892</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28860348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2017-314324</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Piano S, Bartoletti M, Tonon M, et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut. 2017;67(10):1892&#8211;9.<pub-id pub-id-type="pmid">28860348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2017-314324</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>